Publication | Open Access

Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial

RheumatologyJuvenile Idiopathic ArthritisPediatricsOsteoarthritisSafety TrialInflammatory Rheumatic DiseasePaediatric RheumatologyPharmacotherapyMedicineInflammatory ArthritisPhase 3Systemic Juvenile Idiopathic Arthritis